Journal
EPILEPSIA
Volume 54, Issue -, Pages 103-105Publisher
WILEY-BLACKWELL
DOI: 10.1111/epi.12291
Keywords
Benzodiazepine; GABAergic inhibition; Seizure; Anticonvulsant; Dentate gyrus; IPSC
Categories
Funding
- Biocodex
Ask authors/readers for more resources
Benzodiazepines (BZDs), which enhance -aminobutyric acid (GABA(A)) receptor-mediated inhibition, are the first-line therapy for treatment of status epilepticus (SE). However, pharmacoresistance to BZDs develops rapidly after SE initiation. This is due to an activity-dependent internalization of BZD-sensitive GABA(A) receptors during SE. Stiripentol (STP) is a positive allosteric modulator of GABA(A) receptors with a unique subunit selectivity profile. We report that in a rodent model of SE, STP terminates behavioral seizures and remains effective in established SE when seizures have become BZD resistant. The anticonvulsant effects of STP are age dependent, with greater potency in juvenile animals. Whole cell recordings from dentate granule cells in hippocampal slices reveal that STP potentiates GABAergic inhibitory postsynaptic currents (IPSCs) and tonic GABAergic currents by acting at a site on the GABA(A) receptor that is separate from the benzodiazepine binding site. This potentiation persists in established SE, whereas potentiation of GABAergic inhibition by BZDs is lost. STP potentiates IPSCs in juvenile animals with greater potency than in adult animals. We suggest that STP, either alone or as add-on therapy, may prove useful in treating established and BZD-resistant status epilepticus. Furthermore, STP may be particularly effective in terminating SE in children when SE is most prevalent.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available